Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C22H30N2O.ClH.H2O |
| Molecular Weight | 392.963 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.C[C@H]1CCC[C@@H](C)N1CCC[C@@](O)(C2=CC=CC=C2)C3=NC=CC=C3
InChI
InChIKey=GYTCSFJBULWQKM-XUKLEHFWSA-N
InChI=1S/C22H30N2O.ClH.H2O/c1-18-10-8-11-19(2)24(18)17-9-15-22(25,20-12-4-3-5-13-20)21-14-6-7-16-23-21;;/h3-7,12-14,16,18-19,25H,8-11,15,17H2,1-2H3;1H;1H2/t18-,19+,22-;;/m1../s1
| Molecular Formula | C22H30N2O |
| Molecular Weight | 338.4864 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
DOI: 10.1111/j.1527-3466.1983.tb00446.x | https://www.ncbi.nlm.nih.gov/pubmed/3241147 | https://www.ncbi.nlm.nih.gov/pubmed/1381764
Curator's Comment: description was created based on several sources, including:
DOI: 10.1111/j.1527-3466.1983.tb00446.x | https://www.ncbi.nlm.nih.gov/pubmed/3241147 | https://www.ncbi.nlm.nih.gov/pubmed/1381764
Pirmenol is an antiarrhythmic agent, which exhibits effects on the fast action potential similar to other class 1 membrane active antiarrhythmic agents. Pirmenol depresses not only the fast Na+ channel, but also others, such as the slow Ca2+ and K+ channels. Pirmenol had sevenfold lower affinity for glandular-type muscarinic receptors (M3) than for cardiac-type muscarinic receptors (M2). This medicine regulates disturbed pulse by acting on the cardiac muscle. Usually, used for treatment of tachyarrhythmia (ventricular). The most commonly reported adverse reactions include constipation, discomfort in stomach, difficulty in urination (urinary retention), headache, insomnia, bitterness in the mouth, nausea, dry mouth and palpitation. Lidocaine, procainamide and quinidine a greater degree of arrhythmia conversion occurred when dosed 15 min after pirmenol than when these agents were dosed alone.
CNS Activity
Originator
Sources: https://www.google.com/patents/US4112103
Curator's Comment: http://www.chemdrug.com/article/8/3284/16419223.html
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Fast sodium-channels (rabbit) |
|||
Target ID: Slow potassium channels (rabbit) |
|||
Target ID: Slow calcium channels (rabbit) Sources: https://www.ncbi.nlm.nih.gov/pubmed/3241147 |
|||
Target ID: 1.00715344E8 Gene Symbol: Chrm2 |
|||
Target ID: 1.00379232E8 Gene Symbol: Chrm3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1381764 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PIMENOL Approved UseDrug is used for the treatment of tachyarrhythmia (ventricular). |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Progressive facilitation of antegrade conduction via an accessory pathway in a patient with Wolff-Parkinson-White syndrome and permanent atrial fibrillation. | 2005-12 |
|
| A patient responding to combined therapy with pirmenol and midodrine for refractory neurally mediated syncope complicated by prostatic hypertrophy. | 2004-09 |
|
| Pharmacodynamics and pharmacokinetics of oral pirmenol. | 1987-10 |
|
| Pirmenol, a new antiarrhythmic agent: initial study of efficacy, safety and pharmacokinetics. | 1982-02 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9600665
The IC50 of pirmenol for acetylcholine- and adenosine-induced current was about 1 and 8 microM in a single atrial myocytes
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:41:48 GMT 2025
by
admin
on
Mon Mar 31 21:41:48 GMT 2025
|
| Record UNII |
98737Y0095
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
98737Y0095
Created by
admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
|
PRIMARY | |||
|
76965981
Created by
admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |